Name: Latest research reports of Abbott India Ltd. authored by JM Financial and published by - Trendlyne research reports.
Item: Abbott India Ltd.
Rating: 5
Author: JM Financial

Abbott India Ltd.

NSE: ABBOTINDIA | BSE: 500488 | ISIN: INE358A01014 | Industry: Pharmaceuticals
| Expensive Performer

31215.5000 143.20 (0.46%)

NSE Mar 25, 2025 13:02 PM

Near 52W High of ₹31898.95

Volume: 4,439

Abbott India Ltd.

31 Aug 2018

31215.50

0.46%

Abbott India

Buy: Abbott India Ltd.

JM Financial

Cyclical low multiples and asset turns make a strong BUY case ABB India is trading at -1 standard deviation of its median forward PE multiple and fixed asset turns are at a 15-year low (4.1x vs high of 10.9x), thus creating headroom for outperformance as operating leverage benefits are likely to drive strong profitability growth. Further, a bulk of order inflow in 1HCY18 is driven by high margin segments of exports (+14%) and service (+47%) orders, presenting a healthy sales mix for CY18-19. Order inflow outlook remains steady as multiple digitalisation orders with longer conversion cycle are underway and are preceded by pilot projects in industries like cement, paint, F&B; and oil &...

Number of FII/FPI investors decreased from 85 to 78 in Dec 2024 qtr